Американское общество гирудотерапии

von Willebrand factor A1 domain can adequately substitute for A3 domain in recruitment of flowing platelets to collagen

Research article published in J Thromb Haemost (2006)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportФармакология секрета слюнных желёзРазработка лекарственных препаратовBonnefoy A et al. · J Thromb Haemost, 2006

Abstract

BACKGROUND: Binding of von Willebrand factor (VWF) to platelet GPIbalpha and to collagen is attributed to VWF A1 and A3 domains, respectively. OBJECTIVES: Using VWF, VWF lacking A1 (DeltaA1-VWF) or A3 (DeltaA3-VWF) and VWF with defective A3 (H1786A-VWF), in combination with recombinant A1 (residues 1262-1492) or A3 (residues 1671-1878), fused to glutathione-S-transferase (GST-A1 and GST-A3), we have re-investigated the role of A1 in platelet recruitment to surfaces of collagen. METHODS AND RESULTS: In flow, measurable binding of DeltaA3-VWF occurred to horse tendon, but also to human type III collagen. GST-A1 and GST-A3 both competed for binding of DeltaA1-VWF and DeltaA3-VWF to horse tendon collagen fibrils in static conditions and to human collagen III during plasmon surface resonance studies, substantiating overlapping binding sites on both collagens for A1 and A3. Heparin did not affect A3-mediated binding of VWF and DeltaA1-VWF, but inhibited binding to horse tendon collagen of GST-A1 and DeltaA3-VWF. Furthermore, A1-mediated binding to type III collagen of DeltaA3-VWF binding was strongly salt-sensitive. During perfusions at wall shear rate 2500 s(-1) of calcein-labeled platelets in reconstituted blood, DeltaA3-VWF and H1786A-VWF triggered platelet binding to horse tendon collagen comparably and as potently as VWF, and to human type III collagen, only fivefold less potently, DeltaA1-VWF being inactive. Additional flow-controlled interaction studies with DeltaA3-VWF, H1786A-VWF, the collagen-VWF antagonist saratin, heparin and the VWF neutralizing antibody 82D6A3 confirmed that H1786A-VWF binds to collagen exclusively via A1. CONCLUSION: Hence, in shear forces the VWF A1 domain can assume the role of A3 to trigger substantial platelet recruitment to human collagen fibres.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsBinding SitesBlood PlateletsCollagenDose-Response Relationship, DrugGlutathione TransferaseHorsesHumansPlatelet AdhesivenessProtein BindingProtein Structure, TertiaryRecombinant Proteins

Резюме

Binding of von Willebrand factor (VWF) to platelet GPIbalpha and to collagen is attributed to VWF A1 and A3 domains, respectively.

Почему это важно для гирудотерапии

This study re-investigated the roles of von Willebrand factor (VWF) A1 and A3 domains in platelet recruitment to collagen surfaces, using domain-deleted VWF variants, recombinant domain fusion proteins, flow-chamber perfusion assays, and several antagonists including the collagen-VWF antagonist saratin. Saratin was used alongside heparin and antibody 82D6A3 in flow-controlled interaction studies confirming that H1786A-VWF binds to collagen exclusively via A1, and that the A1 domain can assume the role of A3 in triggering platelet recruitment under shear. The abstract does not mention leeches or identify saratin's biological origin, so no hirudotherapy connection can be drawn from this article. Caveat: This is primarily a VWF domain biology study; saratin appears only as a research reagent and no therapeutic, leech-related, or dosing claims are made.

Цитирование

von Willebrand factor A1 domain can adequately substitute for A3 domain in recruitment of flowing platelets to collagen.

Bonnefoy A et al. · J Thromb Haemost, 2006

Связанный клинический контекст

Узнайте, как это исследование связано с клинической практикой

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.